JUBILANT PHARMOVA LTD Fair Value
JUBLPHARMA · Healthcare · Current price ₹907.55
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹416 | 7% ROE fading to 12% over ~3 yrs, on ₹445 book |
| Relative P/E | ₹973 | EPS × 38.9 peer-median P/E |
| Graham floor | ₹501 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹1,166 | Street consensus 12-month target price |
Is JUBILANT PHARMOVA LTD undervalued?
DocStoX estimates the fair value of JUBILANT PHARMOVA LTD at ₹690 per share, versus the current market price of ₹908. That puts the stock about -24.0% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹416), Relative P/E (₹973), Graham floor (₹501), Analyst target (₹1,166). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹416 (bear) to ₹690 (base) to ₹1,166 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on JUBILANT PHARMOVA LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.